News & Publications – Sionna Therapeutics

Press Releases

June 6, 2022

Sionna Therapeutics Announces Appointment of Paul Clancy to Board of Directors

April 19, 2022

Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules with the Potential to Fully Restore CFTR Function in Cystic Fibrosis

Supporting Scientific Literature

Nature Chemical Biology | August 2, 2021

A topological switch in CFTR modulates channel activity and sensitivity to unfolding

Journal of Cystic Fibrosis | January 3, 2020

Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR

Journal of Molecular Biology | January 16, 2015

Restoration of NBD1 thermal stability is necessary and sufficient to correct ∆F508 CFTR folding and assembly

Journal of Cystic Fibrosis | March 14, 2014

Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data

Nature Chemical Biology | May 12, 2013

Mechanism-based corrector combination restores ΔF508-CFTR folding and function

Cell | January 20, 2012

Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function

PLOS ONE | November 30, 2010

The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain

Media Contact

Press Releases

Supporting Scientific Literature